A 62-year-old man with ischemic cardiomyopathy and LVEF 33%. He is on Lisinopril 15 mg po daily, Spironolactone 12.5 mg po daily, Dapagliflozin 10 mg po daily. His BP 110/70 mmHg, HR 72 bpm. You want to add a beta-blocker, which one would you choose to comply with a guideline-directed choice?
سؤال مجاني 1 من 10 اليوم · اشترك وكمّل بدون حد
اعرض الإجابة
الإجابة والشرح
ادخل لحسابك عشان نحفظ إجاباتك ونوريك أخطاءك.
الإجابة: B. Bisoprolol 5 mg po daily
In HFrEF only specific beta-blockers have proven mortality benefit: bisoprolol, carvedilol and metoprolol succinate. Bisoprolol is therefore the guideline-directed choice. Propranolol (short- or long-acting) and nadolol are non-selective beta-blockers that are not part of guideline HF therapy.
ليش كل خيار صح أو غلط
-
A
ليش غلط
The beta-blockers listed as improving mortality in HFrEF are metoprolol succinate, carvedilol and bisoprolol; propranolol is not among them.
✓ Step-Up To Medicine 6th (HF).pdf · p. 8 -
B
ليش صح
Bisoprolol is one of the three beta-blockers (with metoprolol succinate and carvedilol) shown to improve mortality in HFrEF.
✓ Step-Up To Medicine 6th (HF).pdf · p. 8 -
C
ليش غلط
The beta-blockers listed as improving mortality in HFrEF are metoprolol succinate, carvedilol and bisoprolol; long-acting propranolol is not among them.
✓ Step-Up To Medicine 6th (HF).pdf · p. 8 -
D
ليش غلط
The beta-blockers listed as improving mortality in HFrEF are metoprolol succinate, carvedilol and bisoprolol; nadolol is not among them.
✓ Step-Up To Medicine 6th (HF).pdf · p. 8
- المصدر
- Step-Up To Medicine 6th (HF).pdf · p. 8
(Y4)-(M B) HF.pdf · p. 5 - المحاضرة
- Heart Failure · Cardiology · Module B
- ظهر في
- MED43 ♂ Quiz B